La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cyclacel Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 4/6

Cyclacel Pharmaceuticals possède un total de capitaux propres de $999.0K et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $8.2M et de $7.2M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$6.00m
Fonds propres	US$999.00k
Total du passif	US$7.19m
Total des actifs	US$8.19m

Mises à jour récentes de la santé financière

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Aug 17

Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Apr 15

Recent updates

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Aug 17

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

Aug 07

Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Apr 15

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CYCC ( $7.7M ) dépassent ses passifs à court terme ( $7.2M ).

Passif à long terme: Les actifs à court terme de CYCC ( $7.7M ) dépassent ses passifs à long terme ( $5.0K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: CYCC est sans dette.

Réduire la dette: CYCC n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CYCC dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: CYCC dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 18.2 % chaque année

Cyclacel Pharmaceuticals Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Cyclacel Pharmaceuticals Receives Subsequent Non-Compliance Notice from Nasdaq Regarding Nasdaq Listing Rule 5550(b)(1)

Cyclacel Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq Related to Shareholder's Equity

Cyclacel Pharmaceuticals Receives a Written Notice from the Nasdaq Stock Market

Cyclacel Pharmaceuticals, Inc. announced delayed 10-Q filing

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Recent updates

Cyclacel Pharmaceuticals Receives Subsequent Non-Compliance Notice from Nasdaq Regarding Nasdaq Listing Rule 5550(b)(1)

New major risk - Financial position

Consensus revenue estimates decrease by 11%, EPS upgraded

No longer forecast to breakeven

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as Precision Medicine for Cancer

New major risk - Negative shareholders equity

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding

Cyclacel Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq Related to Shareholder's Equity

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

Insufficient new directors

Cyclacel Pharmaceuticals, Inc. Announces Board Changes

Cyclacel Pharmaceuticals, Inc. Announces Executive Changes

Cyclacel Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.525241 million.

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Cyclacel Pharmaceuticals Receives a Written Notice from the Nasdaq Stock Market

Cyclacel Pharmaceuticals, Inc. announced delayed 10-Q filing

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Price target decreased to US$18.00

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Cyclacel Pharmaceuticals, Inc. Reports Preliminary Data from its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients with Solid Tumors and Lymphoma at ENA 2022

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Cyclacel Pharmaceuticals, Inc. Appoints Kenneth M. Ferguson as a Class 1 Director

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$20.00

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients with Advanced Solid Tumors and Lymphomas

Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?

Price target decreased to US$20.00

Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)

Cyclacel Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients with Advanced Solid Tumors and Aggressive Lymphomas

Cyclacel Pharmaceuticals Announces Management Changes

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Cyclacel issues key business objectives for 2021

Cyclacel Pharmaceuticals Announces the Election of Brian Schwartz, M.D. to Its Board of Directors

Cyclacel Pharma inks securities purchase agreement for $7M

Cyclacel Pharmaceuticals, Inc. Appoints Karin L. Walker as Class 1 Director

Cyclacel Pharmaceuticals EPS misses by $1.74

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 11, 2020

Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients with Advanced Solid Tumors At the EORTC-NCI-AACR Symposium 2020

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines